Lara M. Mollé
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lara M. Mollé has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Angus Philip Raynor Johnston
Monash University
2 shared publications - Cameron H. Smyth
Drug Delivery, Disposition and Dynamics Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia
2 shared publications - Daniel Yuen
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3010, Australia
1 shared publication - Moore Z. Chen
Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
1 shared publication - Victoria McLeod
Drug Delivery, Disposition and Dynamics Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by Wiley in Small Science
- Vol. 6 (5) , e70313
Entry Without Expression: Internalisation Does Not Predict mRNA Translation for Targeted Lipid Nanoparticles
Lipid nanoparticle (LNP) delivery systems offer efficient encapsulation and protection of mRNA, making them a popular platform in nucleic acid therapeutics, including mRNA vaccines. Conventional LNPs rely on non‐specific cellular interactions and internalisation which can result in poor delivery to target cells and increased off‐target delivery. Surface functionalization of LNPs with antibodies can enhance target cell accumulation, reducing off target effects. However, selecting antibody‐receptor pairs based on abundance does not result in optimal delivery. Here, we present a novel approach to quantify internalisation and mRNA delivery efficiency of antibody‐functionalised LNP/mRNA in primary human T and B cells. By targeting LNPs to a range of clinically relevant T and B cell receptors, we demonstrate that LNP internalisation does not necessarily predict successful mRNA delivery. Our findings highlight that receptor mediated internalisation can improve targeted delivery of LNPs, however favourable receptor‐specific post‐internalisation trafficking of LNP/mRNA is critical to successful cytosolic mRNA release and translation.
- 21 May 2026
- Published by Wiley in Small Science
- Vol. 6 (5) , e70313
Open AccessEntry Without Expression: Internalisation Does Not Predict mRNA Translation for Targeted Lipid Nanoparticles
Lipid nanoparticle (LNP) delivery systems offer efficient encapsulation and protection of mRNA, making them a popular platform in nucleic acid therapeutics, including mRNA vaccines. Conventional LNPs rely on non‐specific cellular interactions and internalisation which can result in poor delivery to target cells and increased off‐target delivery. Surface functionalization of LNPs with antibodies can enhance target cell accumulation, reducing off target effects. However, selecting antibody‐receptor pairs based on abundance does not result in optimal delivery. Here, we present a novel approach to quantify internalisation and mRNA delivery efficiency of antibody‐functionalised LNP/mRNA in primary human T and B cells. By targeting LNPs to a range of clinically relevant T and B cell receptors, we demonstrate that LNP internalisation does not necessarily predict successful mRNA delivery. Our findings highlight that receptor mediated internalisation can improve targeted delivery of LNPs, however favourable receptor‐specific post‐internalisation trafficking of LNP/mRNA is critical to successful cytosolic mRNA release and translation.
- Open Access
- 23 November 2022
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 14 (6) , e1809
Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery
Nucleic acid therapeutics can be used to control virtually every aspect of cell behavior and therefore have significant potential to treat genetic disorders, infectious diseases, and cancer. However, while clinically approved to treat a small number of diseases, the full potential of nucleic acid therapeutics is hampered by inefficient delivery. Nucleic acids are large, highly charged biomolecules that are sensitive to degradation and so the approaches to deliver these molecules differ significantly from traditional small molecule drugs. Current studies suggest less than 1% of the injected nucleic acid dose is delivered to the target cell in an active form. This inefficient delivery increases costs and limits their use to applications where a small amount of nucleic acid is sufficient. In this review, we focus on two of the major barriers to efficient nucleic acid delivery: (1) delivery to the target cell and (2) transport to the subcellular compartment where the nucleic acids are therapeutically active. We explore how nanoparticles can be modified with targeting ligands to increase accumulation in specific cells, and how the composition of the nanoparticle can be engineered to manipulate or disrupt cellular membranes and facilitate delivery to the optimal subcellular compartments. Finally, we highlight how with intelligent material design, nanoparticle delivery systems have been developed to deliver nucleic acids that silence aberrant genes, correct genetic mutations, and act as both therapeutic and prophylactic vaccines.This article is categorized under: Nanotechnology Approaches to Biology > Cells at the Nanoscale Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Biology‐Inspired Nanomaterials > Lipid‐Based Structures
- 23 November 2022
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 14 (6) , e1809
Open AccessNanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery
Nucleic acid therapeutics can be used to control virtually every aspect of cell behavior and therefore have significant potential to treat genetic disorders, infectious diseases, and cancer. However, while clinically approved to treat a small number of diseases, the full potential of nucleic acid therapeutics is hampered by inefficient delivery. Nucleic acids are large, highly charged biomolecules that are sensitive to degradation and so the approaches to deliver these molecules differ significantly from traditional small molecule drugs. Current studies suggest less than 1% of the injected nucleic acid dose is delivered to the target cell in an active form. This inefficient delivery increases costs and limits their use to applications where a small amount of nucleic acid is sufficient. In this review, we focus on two of the major barriers to efficient nucleic acid delivery: (1) delivery to the target cell and (2) transport to the subcellular compartment where the nucleic acids are therapeutically active. We explore how nanoparticles can be modified with targeting ligands to increase accumulation in specific cells, and how the composition of the nanoparticle can be engineered to manipulate or disrupt cellular membranes and facilitate delivery to the optimal subcellular compartments. Finally, we highlight how with intelligent material design, nanoparticle delivery systems have been developed to deliver nucleic acids that silence aberrant genes, correct genetic mutations, and act as both therapeutic and prophylactic vaccines.This article is categorized under: Nanotechnology Approaches to Biology > Cells at the Nanoscale Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Biology‐Inspired Nanomaterials > Lipid‐Based Structures